|
11/10/2020
|
Summary ToggleNovus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16
|
|
11/02/2020
|
Summary ToggleNovus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis
|
|
10/02/2020
|
Summary ToggleNovus Therapeutics Announces One-for-Eighteen Reverse Stock Split
|
|
09/15/2020
|
Summary ToggleNovus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
|
|
09/14/2020
|
Summary ToggleNovus Therapeutics Announces Acquisition of Anelixis Therapeutics
|
|
06/01/2020
|
Summary ToggleNovus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
|
|
05/15/2020
|
Summary ToggleNovus Therapeutics Reports First Quarter 2020 Financial Results
|
|
03/17/2020
|
Summary ToggleNovus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results
|
|
03/02/2020
|
Summary ToggleNovus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media
|
|
01/13/2020
|
Summary ToggleNovus Therapeutics Provides Update on OP0201
|
